Is PT-141 (Bremelanotide) Legal in South Carolina?

The Short Answer on Legality

PT-141, sold as Vyleesi, is a legal prescription medication in South Carolina when dispensed by a licensed pharmacist after a valid prescription from a licensed prescriber. The sticking point is compounded bremelanotide. The FDA placed bulk bremelanotide on its Category 2 list in 2023, signaling that compounded versions present clinical concerns and should not be made by 503A or 503B facilities except under narrow circumstances. This is a federal restriction that applies in every state, South Carolina included.

What "Legal" Actually Means Here

Legality for a prescription drug exists at two levels: federal and state. At the federal level, the FDA controls what can be manufactured, compounded, and distributed. At the state level, the South Carolina Board of Pharmacy and the SC Department of Labor, Licensing and Regulation (LLR) govern who can prescribe and dispense. Both layers must be satisfied simultaneously.

South Carolina has no separate statute that independently bans or uniquely permits bremelanotide. The state's pharmacy and medical practice laws follow the federal framework. A provider operating inside that framework is acting lawfully.

The Branded vs. Compounded Distinction

Vyleesi (brand name) is a finished drug product approved by the FDA under New Drug Application 210557. Any licensed South Carolina physician can write a prescription for it, and any South Carolina licensed pharmacy can fill it. AMAG Pharmaceuticals' FDA approval is publicly documented in the FDA's drug database.

Compounded bremelanotide is a different matter entirely, addressed in detail in the section below.

FDA Approval: What Vyleesi Is and Is Not Approved For

The FDA approved bremelanotide injection (Vyleesi) on June 21, 2019, specifically for premenopausal adult women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire accompanied by marked distress or interpersonal difficulty. The approval does not extend to postmenopausal women or to men. The full prescribing information is available on the FDA's accessdata portal.

Clinical Evidence Behind the Approval

The key trials supporting FDA approval were the RECONNECT studies, two replicate Phase 3 randomized controlled trials (RECONNECT Study A and Study B) in premenopausal women with HSDD. Across both trials (combined N approximately 1,247), women who received bremelanotide 1.75 mg subcutaneously reported statistically significant improvements on the Female Sexual Function Index desire domain and on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) compared with placebo. The RECONNECT trial results were published in Obstetrics and Gynecology.

Nausea was the most common adverse effect, reported by approximately 40% of bremelanotide-treated subjects versus 1% of placebo subjects. Transient increases in blood pressure averaging 2 mmHg systolic occurred in treated patients. The FDA label carries a warning against use in patients with cardiovascular disease for this reason.

Mechanism of Action

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It binds primarily to MC3R and MC4R receptors in the central nervous system, modulating dopaminergic and serotoninergic pathways involved in sexual motivation. This mechanism differs from phosphodiesterase-5 inhibitors (sildenafil, tadalafil) and from flibanserin (Addyi), which acts on serotonin receptors. A detailed pharmacology review appears in the NIH bookshelf entry for bremelanotide.

Federal Compounding Law: 503A, 503B, and the Bulk Substances List

Understanding compounded bremelanotide's legal status requires understanding two sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Section 503A: Traditional Compounding Pharmacies

Section 503A allows state-licensed pharmacies to compound drugs for individual patients based on a valid prescription. However, 503A pharmacies cannot compound drugs that are essentially a copy of an approved product, and they cannot use bulk drug substances that are on the FDA's "difficult-to-compound" Category 2 list. The FDA's compounding FAQ clarifies these restrictions.

In October 2023, the FDA finalized its decision placing bulk bremelanotide on the Category 2 difficult-to-compound list. This means 503A pharmacies may not compound preparations using bulk bremelanotide unless the FDA determines there is a clinical need that cannot be met by the approved product. As of this article's review date, no such clinical determination has been made for bremelanotide.

Section 503B: Outsourcing Facilities

Section 503B outsourcing facilities may compound drugs without individual prescriptions and can sell to hospitals and clinicians. They are held to Current Good Manufacturing Practice (CGMP) standards. The same bulk substances restrictions apply. Bulk bremelanotide on the Category 2 list means 503B facilities also face restrictions on its compounding.

What Category 2 Actually Means

The FDA uses three categories when evaluating bulk substances proposed for compounding:

• Category 1: Appropriate for compounding (may be used).
• Category 2: Should not be compounded because the bulk substance presents safety risks, lacks clinical need evidence, or raises other concerns.
• Category 3: Under review, no final determination yet.

Bremelanotide was placed in Category 2 after the FDA reviewed public comments and concluded the evidence did not support a finding that compounding it is appropriate for patient populations. The FDA's bulk substances list with category assignments is maintained at FDA.gov.

This classification is federal law. It applies uniformly in South Carolina and every other state.

South Carolina State Law and the Pharmacy Board

South Carolina does not have a standalone bremelanotide statute. State-level regulation comes through two primary channels: the SC Board of Pharmacy and the SC LLR Medical Practice Act.

SC Board of Pharmacy

The South Carolina Board of Pharmacy licenses pharmacies operating within the state and sets compounding standards consistent with federal law. The board follows United States Pharmacopeia (USP) chapters <795> and <797> as baseline standards and expects licensed pharmacies to comply with FD&C Act requirements, including the 503A bulk substances restrictions. The SC Board of Pharmacy's rules are available through the SC LLR website.

A pharmacy in South Carolina that compounds bremelanotide from bulk substance after the FDA's Category 2 designation would be operating outside federal compliance, which also places it outside the scope of lawful practice under South Carolina rules. No state pharmacy board rule overrides a federal restriction of this type.

SC Medical Practice Act and Prescribing

Licensed physicians, nurse practitioners, and physician assistants in South Carolina may prescribe FDA-approved drugs for off-label uses as a matter of standard medical practice. A South Carolina physician could legally prescribe Vyleesi (branded bremelanotide) to a man experiencing sexual dysfunction, for example, even though the FDA has not approved that use. Off-label prescribing is legal. The limitation remains on the dispensing side: the pharmacy must dispense an FDA-approved product, not a compounded version made from restricted bulk substances.

No South Carolina-Specific Gray Area

Some states have enacted their own compounding exemptions or peptide-specific regulations. South Carolina has not. The legal analysis here is therefore simpler than in some other states: follow federal law, and South Carolina law is satisfied. Any claims that South Carolina independently authorizes compounded bremelanotide outside the federal framework are not supported by any identifiable statute or board rule as of the review date of this article.

How to Get PT-141 (Bremelanotide) Legally in South Carolina

Getting bremelanotide legally in South Carolina means getting a prescription for Vyleesi from a licensed provider and filling it at a licensed pharmacy.

Step 1: Find a Qualified Prescriber

A South Carolina-licensed physician, NP, or PA with prescriptive authority can evaluate you and write a prescription. Specialties with relevant expertise include:

• Gynecology and obstetrics (for premenopausal HSDD)
• Sexual medicine
• Urology (for off-label male use)
• Primary care and internal medicine

The prescriber will need to confirm the diagnosis of HSDD, review cardiovascular history given the blood pressure warning, and document the prescription in the medical record.

Step 2: Telehealth Access

South Carolina law permits telehealth consultations, including with out-of-state providers who are licensed in South Carolina or who operate under applicable interstate compacts. The South Carolina Telehealth Alliance has published guidance supporting expanded telehealth services. HealthRX clinicians licensed in South Carolina can evaluate patients remotely, complete a clinical assessment, and write a prescription that can be filled at a licensed retail or mail-order pharmacy.

Step 3: Filling the Prescription

A valid Vyleesi prescription can be filled at:

• Major retail chains (CVS, Walgreens, Walmart pharmacy)
• Mail-order pharmacies with South Carolina dispensing licenses
• Specialty pharmacies that stock biologics and hormone products

Vyleesi's list price is high without insurance. GoodRx and manufacturer coupons (Palatin Technologies' patient assistance programs) may reduce out-of-pocket cost. Patients should confirm current pricing directly with their pharmacy.

What to Avoid

Purchasing bremelanotide from online vendors marketing it as a "research chemical" or "not for human use" bypasses both federal and state law. These products are not manufactured under CGMP conditions, carry no quality assurance, and have no verified dosing. South Carolina residents purchasing such products assume full legal risk and serious safety risk.

The HealthRX prescribing team follows a three-gate framework before initiating bremelanotide in any patient: (1) confirmed HSDD diagnosis using the FSDS-DAO or equivalent validated tool, with a score indicating clinically meaningful distress; (2) cardiovascular clearance confirming no uncontrolled hypertension and no major adverse cardiac event history; and (3) patient education on the transient blood pressure effect, with a documented understanding that bremelanotide should not be combined with naltrexone or any drug that slows gastric emptying significantly, because absorption of oral medications taken within 1 hour of injection may be reduced. Only after all three gates are cleared does the team proceed to prescribing Vyleesi.

Safety Profile and Prescribing Considerations

Bremelanotide's safety data from the RECONNECT program and post-marketing pharmacovigilance are well-characterized.

Common Adverse Effects

• Nausea: ~40% incidence in clinical trials, typically onset within 1 hour of injection and resolving within 12 hours. Pre-treatment with ondansetron may be considered for patients with significant nausea on trial doses.
• Flushing: ~20% incidence, described as warmth or tingling.
• Injection site reactions: Bruising and localized pain at the subcutaneous injection site.
• Transient hypertension: Mean peak systolic increase of approximately 2 mmHg; in some patients this increase was clinically meaningful. Blood pressure typically returns to baseline within 12 hours.

Contraindications

The FDA label lists known cardiovascular disease as a contraindication because of the blood pressure effect. Patients with hypertension that is not well-controlled should not use bremelanotide without specific physician clearance. Full contraindication details appear in the Vyleesi prescribing information on the FDA accessdata portal.

Drug Interactions

Bremelanotide slows gastric emptying. Co-administration with naltrexone or high-dose oral medications relying on gastric absorption may result in reduced efficacy of those medications. The label advises against use with naltrexone specifically.

Dosing

The approved dose is 1.75 mg subcutaneously in the abdomen or thigh, administered approximately 45 minutes before anticipated sexual activity. Patients should not use more than one dose in 24 hours and should limit use to no more than approximately 8 doses per month based on labeling recommendations.

Addressing the "Research Chemical" Market

A segment of online vendors sells bremelanotide in lyophilized powder or solution form, labeled "for research use only." These products are not legal pharmaceutical preparations. They are not approved by the FDA, not manufactured under CGMP conditions, and not subject to quality control. Purchasing them for personal human use is not protected by any research exemption.

The FDA has issued warning letters to peptide vendors making health claims about unapproved peptide products. A summary of FDA enforcement actions against compounders and unapproved drug sellers appears on the FDA's compounding enforcement page.

South Carolina residents who order such products for personal use risk receiving mislabeled or contaminated material, with no legal recourse and potential customs seizure of the shipment. The far safer path is a physician visit and a Vyleesi prescription.

Frequently Asked Questions